Anti-interleukin therapy in asthma

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 1, 2015, Pages 55-65

  Dunn, R M ^a   Wechsler, M E ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; EOTAXIN; EPSILON OPIATE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; INTERLEUKIN 25; INTERLEUKIN 25 ANTIBODY; INTERLEUKIN 33; INTERLEUKIN 33 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; INTERLEUKIN 9; INTERLEUKIN 9 ANTIBODY; PROSTAGLANDIN; THYMIC STROMAL LYMPHOPOIETIN; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; INTERLEUKIN DERIVATIVE;

ANTI INTERLEUKIN THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; COMORBIDITY; CROSS LINKING; DRUG THERAPY; EOSINOPHIL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; IMMUNE RESPONSE; LUNG FUNCTION; LYMPHOID CELL; MECHANICAL STRESS; MUCOCILIARY CLEARANCE; ONSET AGE; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DESIGN; EOSINOPHILIA; HUMAN; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; UNITED STATES;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DESIGN; EOSINOPHILIA; HUMANS; INDIVIDUALIZED MEDICINE; INFLAMMATION; INTERLEUKINS; MOLECULAR TARGETED THERAPY; UNITED STATES;

EID: 84927171631     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.11     Document Type: Article

References (100)

1. Center for Disease Control. Asthma's impact on the nation. [updated 7 August 2014]. (2014). http://www.cdc.gov/asthma/impacts- nation/default.htm
2. Center for Disease Control. Asthma in the US, vital signs [Online 2011] [updated May 2011]. (2011). http://www.cdc.gov/vitalsigns/asthma
3. Moorman, J.E. et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill. Summ. 56, 1-54 (2007).
4. Akinbami, L.J. et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief 1-8 (2012).
5. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J. Allergy Clin. Immunol. 120 (suppl.), S94-S138 (2007).
6. GINA Report, Global Strategy for Asthma Managment and Prevention 2014 [updated August 2014; cited 2 September 2014]. (2014). >http://www.ginasthma.org/local/uploads/files/GINA-Report-2014- Aug12.pdf≤
7. Peters, S.P. et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J Med. 363, 1715-1726 (2010).
8. Wechsler, M.E. et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J. Allergy Clin. Immunol. 132, 1295-1302 (2013).
9. Wenzel, S.E. & Busse, W.W. Severe asthma: Lessons from the Severe Asthma Research Program. J. Allergy Clin. Immunol. 119, 14-21; quiz 2-3 (2007).
10. Strunk, R.C. & Bloomberg, G.R. Omalizumab for asthma. N. Engl. J Med. 354, 2689-2695 (2006).
11. Busse, W.W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J Med. 364, 1005-1015 (2011).
12. Cowan, D.C., Cowan, J.O., Palmay, R., Williamson, A. & Taylor, D.R. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 65, 384-390 (2010).
13. Lambrecht, B.N. & Hammad, H. The airway epithelium in asthma. Nat. Med. 18, 684-692 (2012).
14. Kallal, L.E., Schaller, M.A., Lindell, D.M., Lira, S.A. & Lukacs, N.W. CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. Eur. J. Immunol. 40, 1042-1052 (2010).
15. Lambrecht, B.N. & Hammad, H. Lung dendritic cells in respiratory viral infection and asthma: From protection to immunopathology. Annu. Rev. Immunol. 30, 243-270 (2012).
16. Maazi, H., Lam, J., Lombardi, V. & Akbari, O. Role of plasmacytoid dendritic cell subsets in allergic asthma. Allergy 68, 695-701 (2013).
17. Robinson, D.S. et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326, 298-304 (1992).
18. Schoenborn, J.R. & Wilson, C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96, 41-101 (2007).
19. Cosmi, L., Liotta, F., Maggi, E., Romagnani, S. & Annunziato, F. Th17 cells: New players in asthma pathogenesis. Allergy 66, 989-998 (2011).
20. Bacharier, L.B., Jabara, H. & Geha, R.S. Molecular mechanisms of immunoglobulin E regulation. Int. Arch. Allergy Immunol. 115, 257-269 (1998).
21. Her, E., Frazer, J., Austen, K.F. & Owen, W.F. Jr. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J. Clin. Invest. 88, 1982-1987 (1991).
22. Fulkerson, P.C. & Rothenberg, M.E. Targeting eosinophils in allergy, inflammation and beyond. Nat. Rev. Drug Discov. 12, 117-129 (2013).
23. Kita, H. Eosinophils: Multifunctional and distinctive properties. Int. Arch. Allergy Immunol. 161 (suppl. 2), 3-9 (2013).
24. Reber, L., Da Silva, C.A. & Frossard, N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 533, 327-340 (2006).
25. Barnes, P.J. Pathophysiology of allergic inflammation. Immunol. Rev. 242, 31-50 (2011).
26. Saenz, S.A. et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 464, 1362-1366 (2010).
27. Campbell, H.D. et al. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc. Natl. Acad. Sci. USA 84, 6629-6633 (1987).
28. Namkung, J.H. et al. IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans. Allergy 62, 934-942 (2007).
29. Gevaert, P. et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 118, 1133-1141 (2006).
30. Sutton, S.A., Assa'ad, A.H. & Rothenberg, M.E. Anti-IL-5 and hypereosinophilic syndromes. Clin. Immunol. 115, 51-60 (2005).
31. Rosenberg, H.F., Phipps, S. & Foster, P.S. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 119, 1303-1310; quiz 11-12 (2007).
32. Humbert, M., Corrigan, C.J., Kimmitt, P., Till, S.J., Kay, A.B. & Durham, S.R. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am. J. Respir. Crit. Care Med. 156 (pt 1), 704-708 (1997).
33. Shi, H.Z. et al. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am. J. Respir. Crit. Care Med. 157, 204-209 (1998).
34. Leckie, M.J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
35. Kips, J.C. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am. J. Respir. Crit. Care Med. 167, 1655-1659 (2003).
36. Flood-Page, P. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062-1071 (2007).
37. Nair, P. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985-993 (2009).
38. Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973-984 (2009).
39. Haldar, P. et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis. J. Allergy Clin. Immunol. 133, 921-923 (2014).
40. Pavord, I.D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 380, 651-659 (2012).
41. Bel, E.H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189-1197 (2014).
42. Ortega, H.G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198-1207 (2014).
43. Castro, M. et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184, 1125-1132 (2011).
44. Bjermer, L., Lemiere, C., Maspero, J., Ciesielska, M., O'Brien, C. & Zangrilli, J. A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. (Abstract presented at European Respiratory Society Meeting, 2014). 7 September 2014.
45. Corren, J., Weinstein, S., Janka, L., O'Brien, C. & Zangrilli, J. A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. (Abstract presented at European Respiratory Society meeting, 2014). 8 September 2014.
46. Kolbeck, R. et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 125, 1344-1353.e2 (2010).
47. Laviolette, M. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 132, 1086-1096.e5 (2013).
48. Busse, W.W. et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125, 1237-1244.e2 (2010).
49. Clinicaltrials.gov. A phase 3a, repeat dose, open-label, long-term safety study of mepolizumab in asthmatic subjects. (2014). Accessed 2 September 2014.
50. Clinicaltrials.gov. A study to determine long-term safety of mepolizumab in asthmatic subjects. (2014). >http://clinicaltrials. gov/show/NCT02135692≤ Accessed 7 September 2014.
51. Zurawski, S.M., Vega, F. Jr., Huyghe, B. & Zurawski, G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12, 2663-2670 (1993).
52. Humbert, M. et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J. Allergy Clin. Immunol. 99, 657-665 (1997).
53. Saha, S.K. et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J. Allergy Clin. Immunol. 121, 685-691 (2008).
54. Zhu, Z. et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103, 779-788 (1999).
55. Eum, S.Y., Maghni, K., Tolloczko, B., Eidelman, D.H. & Martin, J.G. IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L576-L584 (2005).
56. Zhu, J., Guo, L., Watson, C.J., Hu-Li, J. & Paul, W.E. Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. J. Immunol. 166, 7276-7281 (2001).
57. Takayama, G. et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118, 98-104 (2006).
58. Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011).
59. Noonan, M. et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J. Allergy Clin. Immunol. 132, 567-574.e12 (2013).
60. Scheerens, H. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy 44, 38-46 (2014).
61. Piper, E. et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 41, 330-338 (2013).
62. Chiang, C.H., Tang, Y.C., Lin, M.W. & Chung, M.Y. Association between the IL-4 promoter polymorphisms and asthma or severity of hyperresponsiveness in Taiwanese. Respirology 12, 42-48 (2007).
63. Brusselle, G., Kips, J., Joos, G., Bluethmann, H. & Pauwels, R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am. J. Respir. Cell Mol. Biol. 12, 254-259 (1995).
64. Steinke, J.W. & Borish, L. Th2 cytokines and asthma. Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. 2, 66-70 (2001).
65. Zhu, J., Yamane, H., Cote-Sierra, J., Guo, L. & Paul, W.E. GATA-3 promotes Th2 responses through three different mechanisms: Induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 16, 3-10 (2006).
66. Borish, L.C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J Respir. Crit. Care Med. 160, 1816-1823 (1999).
67. Borish, L.C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
68. Hart, T.K. et al. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130, 93-100 (2002).
69. Clinicaltrials.gov. PIlot study in patients with symptomatic steroidnaive asthma. (2012). http://clinicaltrials.gov/show/NCT00024544
70. Tomkinson, A. et al. A murine IL-4 receptor antagonist that inhibits IL-4-and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. 166, 5792-5800 (2001).
71. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E.B. & Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 370, 1422-1431 (2007).
72. Babatunde, A.O. et al. A phase 2b study of inhaled pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. D101 Asthma Genetics. American Thoracic Society International Conference Abstracts: American Thoracic Society. p. A6179-A.
73. Corren, J. et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181, 788-796 (2010).
74. Wenzel, S. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455-2466 (2013).
75. Clinicaltrials.gov. Long-term safety evaluation of dupilumab in patients with asthma. (2014). >http://clinicaltrials.gov/show/NCT02134028≤ Accessed 2 September 2014.
76. Barczyk, A., Pierzchala, W. & Sozanska, E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 97, 726-733 (2003).
77. Linden, A. Role of interleukin-17 and the neutrophil in asthma. Int. Arch. Allergy Immunol. 126, 179-184 (2001).
78. Bullens, D.M. et al. IL-17 mRNA in sputum of asthmatic patients: Linking T cell driven inflammation and granulocytic influx? Respir. Res. 7, 135 (2006).
79. McKinley, L. et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181, 4089-4097 (2008).
80. Papp, K.A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189 (2012).
81. Busse, W.W. et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 188, 1294-1302 (2013).
82. Clinicaltrials.gov. Safety, tolerability, and efficacy of AIN457 in patients with uncontrolled asthma. http://clinicaltrials.gov/show/NCT01478360 (2014). Accessed 2 September 2014.
83. Nelson, B.H. IL-2, regulatory T cells, and tolerance. J. Immunol. 172, 3983-3988 (2004).
84. Rand, T.H., Silberstein, D.S., Kornfeld, H. & Weller, P.F. Human eosinophils express functional interleukin 2 receptors. J. Clin. Invest. 88, 825-832 (1991).
85. Park, C.S., Lee, S.M., Chung, S.W., Uh, S., Kim, H.T. & Kim, Y.H. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest 106, 400-406 (1994).
86. Busse, W.W. et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial. Am. J. Respir. Crit. CareMed. 178, 1002-1008 (2008).
87. Temann, U.A., Ray, P. & Flavell, R.A. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J. Clin. Invest. 109, 29-39 (2002).
88. Shimbara, A. et al. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma. J. Allergy Clin. Immunol. 105 (pt 1), 108-115 (2000).
89. Oh, C.K., Leigh, R., McLaurin, K.K., Kim, K., Hultquist, M. & Molfino, N.A. A randomized, controlled trial to evaluate the effect of an antiinterleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir. Res. 14, 93 (2013).
90. Govindaraju, V., Michoud, M.C., Al-Chalabi, M., Ferraro, P., Powell, W.S. & Martin, J.G. Interleukin-8: Novel roles in human airway smooth muscle cell contraction and migration. Am. J. Physiol. Cell Physiol. 291, C957-C965 (2006).
91. Chanez, P., Enander, I., Jones, I., Godard, P. & Bousquet, J. Interleukin 8 in bronchoalveolar lavage of asthmatic and chronic bronchitis patients. Int. Arch. Allergy Immunol. 111, 83-88 (1996).
92. Mahler, D.A., Huang, S., Tabrizi, M. & Bell, G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study. Chest 126, 926-934 (2004).
93. Nair, P. et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: A randomized, placebocontrolled clinical trial. Clin. Exp. Allergy 42, 1097-1103 (2012).
94. Ballantyne, S.J. et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol. 120, 1324-1331 (2007).
95. Kearley, J., Buckland, K.F., Mathie, S.A. & Lloyd, C.M. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am. J. Respir. Crit. Care Med. 179, 772-781 (2009).
96. Prefontaine, D. et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 125, 752-754 (2010).
97. Gauvreau, G.M. et al. Effects of an anti-TSLP antibody on allergeninduced asthmatic responses. N. Engl. J. Med. 370, 2102-2110 (2014).
98. Zhou, B. et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6, 1047-1053 (2005).
99. Gauvreau, G.M. et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci. Transl. Med. 6, 243ra85 (2014).
100. Kaye, J. Study of TLR-9 agonist for treatment of allergic asthma discontinued after disappointing results. (Healthcare Professionals Network, 2014).